503b exclusion semaglutide

FDA proposes to exclude semaglutide, tirzepatide on 503B bulks list — Photo by Artem Podrez on Pexels

3 Surprising Things About Semaglutide's 503B Exclusion

3 Surprising Things About Semaglutide's 503B Exclusion The FDA’s proposal to exclude three GLP-1 drugs from the 503B bulks list means clinics can no longer rely on compounding pharmacies for bulk semaglutide, tirzepatide, or liraglutide, forcing them to purchase fully labeled vials. The change aims to curb